Firefly Neuroscience

AIFF

Market cap $33.6M

- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1

Firefly Neuroscience Inc. (NASDAQ: AIFF) shares are up on Friday as the company continues to make strides in its development of brain scan technologies.

Firefly Neuroscience Inc. (NASDAQ: AIFF) shares are up on Wednesday as the company continues to develop its foundation model of the human brain.

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -  - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain - KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.

– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today reported financial results for the three and nine months ended September 30, 2025.

NEW YORK , Oct. 9, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Firefly Neuroscience, Inc. (NASDAQ: AIFF) on behalf of the company's shareholders.  The investigation seeks to determine whether Firefly Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS).

– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to unveil its new ‘CLEAR' (CLeaning EEG ARtifacts) Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled electroencephalogram (EEG) data quality.